Genome writing project aims to rally scientists around virus-proofing cells – Science Magazine
Science Magazine |
Genome writing project aims to rally scientists around virus-proofing cells
Science Magazine Launched in 2016 with the sprawling ambition to build large genomes, the synthetic biology initiative known as Genome Project–write (GP-write) is now, slowly, getting down to specifics. Ahead of a meeting today in Boston, GP-write’s leadership … |
Forbes |
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
Forbes George Church, a Harvard scientist who pioneered the use of the enzyme CRISPR to edit the genes of human cells, will use an alternative, older technology in an effort to recode an entire human genome in hundreds of thousands of locations in order to … Genome ‘writers’ set their first goal: recoding human cells to resist virusesSTAT Genome writing project aims to rally scientists around virus-proofing cellsScience Magazine |
STAT |
Corners of the immunotherapy space are getting crowded. Is that a problem?
STAT here’s an overabundance of copycat drugs in the cancer immunotherapy space, with companies pouring millions into developing drugs that only add incremental value to patients. That was the general consensus from a panel of biotech experts who spoke … |
Newsweek |
Stem Cell Research Will Save Lives, and Congress Needs to Act Now | Opinion
Newsweek This article originally appeared on City Journal. Last month, FDA commissioner Scott Gottlieb and Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, coauthored a special report in the New England Journal of Medicine … |
News-Medical.net |
New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy
News-Medical.net Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are … |
Drug Discovery & Development |
FDA Grants Priority Review to Immunotherapy Combination with …
Drug Discovery & Development Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA, the company’s anti-PD-1 therapy, based … FDA Grants Priority Review for Immunotherapy-Based Lung Cancer …Curetoday.com |